Taiwan Biotech Company (1789) Reports Q4 2025 Financials: EPS at NT$0.17
Taiwan Biotech Company (TWSE: 1789) announced its fourth quarter 2025 financial results, reporting basic earnings per share (EPS) of NT$0.17. The company's revenue for the quarter reached NT$3.163 billion, with a net profit after tax of NT$137 million. Taiwan Biotech operates within the biotechnology and healthcare industry, focusing on active pharmaceutical ingredients (APIs).
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:20 (16h 20m after Collected)
Company Code: 1789
Company Name: Taiwan Biotech Company
Industry: Biotechnology and Healthcare
Year/Quarter: 2025 Q4
Basic Earnings Per Share: NT$0.17
Operating Revenue: NT$3.163 billion
Net Profit After Tax: NT$137 million
Company Name: Taiwan Biotech Company
Industry: Biotechnology and Healthcare
Year/Quarter: 2025 Q4
Basic Earnings Per Share: NT$0.17
Operating Revenue: NT$3.163 billion
Net Profit After Tax: NT$137 million
FAQ
What were Taiwan Biotech Company's earnings per share for Q4 2025?
Taiwan Biotech Company reported basic earnings per share of NT$0.17 for the fourth quarter of 2025.
What was Taiwan Biotech Company's revenue in Q4 2025?
The company's operating revenue for Q4 2025 was NT$3.163 billion.
What was Taiwan Biotech Company's net profit after tax in Q4 2025?
Taiwan Biotech Company's net profit after tax for Q4 2025 was NT$137 million.
What industry does Taiwan Biotech Company operate in?
Taiwan Biotech Company operates in the biotechnology and healthcare industry.